Cel­gene prices $4.5B se­nior notes to help buy Juno; Health Af­fairs study says No­var­tis prices its CAR-T too high

→ Cel­gene $CELG has priced four se­ries of se­nior un­se­cured notes for an ag­gre­gate of $4.5 bil­lion, a por­tion of which will be used to pay for a slice of its $9 bil­lion ac­qui­si­tion of Juno Ther­a­peu­tics (an­nounced in Jan­u­ary). Of the new notes, $500 mil­lion will ma­ture in 2021 with an an­nu­al in­ter­est rate of 2.875%, $1 bil­lion will ma­ture in 2023 at 3.25%. $1.5 bil­lion will ma­ture in 2028 at 3.9%, and $1.5 bil­lion will ma­ture in 2048 at 4.55%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER